Forbion Growth Management B.V.
SEC CIK 1918318 · EDGAR
BoughtSold
Most active insiders at NAMS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Davidson Michael H. | CEO, Dir | $226.5K | $25.33M |
| 2 | Kooij Louise Frederika | CAO | — | $16.75M |
| 3 | Kastelein Johannes Jacob Pieter | CSO, Dir | — | $14.26M |
| 4 | Somaiya Mayur Ian | CFO | — | $3.43M |
| 5 | LANGE LOUIS G | Dir | — | $2.19M |
| 6 | Smither John W | Dir | — | $40.5K |
| 7 | Gunning Robert William | VP, Ctrl | — | — |
| 8 | van der Kamp Hilde Johanna | Dir | — | — |
| 9 | McKenna Mark C. | Dir | — | — |
| 10 | Gulfo Adele M. | Dir | — | — |
Forbion Growth Management B.V. made no open-market trades at NAMS in the last 12 months.
Transactions 2
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MTI | 2024-12-12 | 2024-12-10+ | NAMS | NewAmsterdam Pharma Co N.V. | Forbion Growth Management B.V. | 10% | S - Sale | $25.40 | -462.3K | 11.52M | -4% | -$11.74M |
| 2024-11-01 | 2024-10-30 | ENGN | enGene Therapeutics Inc. | Forbion Growth Management B.V. | 10% | P - Purchase | $8.90 | +561.8K | 3.03M | +23% | +$5.00M |
Purchase Sale Sale after option exercise All abbreviations